Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

Collegium Pharmaceutical completed its acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million. The acquisition is expected to be immediately accretive and includes patent protection through 2037. Collegium raised its 2026 financial guidance, projecting total product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million, with expected annual synergies exceeding $50 million.